NUVASIVE, INC. (NASDAQ:NUVA) Files An 8-K Financial Statements and Exhibits

NUVASIVE, INC. (NASDAQ:NUVA) Files An 8-K Financial Statements and Exhibits
Item 9.01

Story continues below

Financial Statements and Exhibits.


Press release issued by NuVasive, Inc. on December 12, 2017

EX-99.1 2 nuva-ex991_6.htm EX-99.1 nuva-ex991_6.htm Exhibit 99.1     NEWS RELEASE   NUVASIVE TO ACQUIRE SAFEPASSAGE   • Expands the Company’s Position as the Leading Provider of Intraoperative Neurophysiological Monitoring Services with Complementary Geographic Footprint   • Adds World-Class Clinical Expertise to NuVasive Clinical Services Leadership Team   • Drives Greater Utilization and Integration of NuVasive’s Procedurally-Integrated Portfolio SAN DIEGO – December 12,…
To view the full exhibit click here


Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.

An ad to help with our costs